Pracinostat (SB939)

Catalog No.S1515

For research use only.

Pracinostat (SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. Pracinostat (SB939) induces apoptosis in tumor cells. Phase 2.

Pracinostat (SB939) Chemical Structure

CAS No. 929016-96-6

Selleck's Pracinostat (SB939) has been cited by 19 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Other HDAC Products

Biological Activity

Description Pracinostat (SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. Pracinostat (SB939) induces apoptosis in tumor cells. Phase 2.
Features A new histone deacetylase inhibitor based on hydroxamic acid, with improved physicochemical, pharmaceutical, and pharmacokinetic properties.
Targets
HDAC10 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
HDAC5 [1]
(Cell-free assay)
HDAC1 [1]
(Cell-free assay)
HDAC4 [1]
(Cell-free assay)
Click to View More Targets
40 nM 43 nM 47 nM 49 nM 56 nM
In vitro

SB939 has a 100-fold greater selectivity for HDACs than for Zn-binding non-HDAC enzymes, receptors, and ion channels. SB939 is a potent inhibitor of HDAC class I isoenzymes, HDAC1, HDAC2, HDAC3 and HDAC8 with the IC50 values ranging from 43 nM to 140 nM. SB939 inhibits HDAC class II isoenzymes , HDAC4, HDAC5, HDAC7, HDAC9 and HDAC10 significantly with the IC50 values ranging from 40 nM to 137 nM, with the exception of HDAC6 which shows IC50 of 1008 nM. It markedly inhibits HDAC11 of the HDAC class IV enzymes with IC50 of 93 nM, but shows no inhibitory activity against SIRT 1 of the class III HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, especially Leukemia cells and cutaneous T-cell Lymphoma cells with IC50 values ranging from 50 nM (H9 cells) to 170 nM (HEL92.1.7 cells). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 cells M1vDN3Bzd2yrZnXyZZRqd25iYYPzZZk> NHj2R|E1QCCq M{TlfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlE4KM7:TR?= MmruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUm1OVUoRjJ2MUG5OVU2RC:jPh?=
NCI-H460 cells MVzQdo9tcW[ncnH0bY9vKGG|c3H5 NHHxW2Y1QCCq NX\xT|dOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkKyJO69VQ>? NFPvTlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxPVU2PSd-MkSxNVk2PTV:L3G+
HCT116 cells MmHrVJJwdGmoZYLheIlwdiCjc4PhfS=> Mm\LOFghcA>? MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlI1KM7:TR?= M4T2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5OVU2Lz5{NEGxPVU2PTxxYU6=
MDA-MB-435 cells MmLHVJJwdGmoZYLheIlwdiCjc4PhfS=> MYi0PEBp NHqzfYtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12M{WgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmsJGdKPTB;MD60PEDPxE1? NXWySGl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVk2PTVpPkK0NVE6PTV3PD;hQi=>
OVCAR5 cells NF7JSFRRem:uaX\ldoF1cW:wIHHzd4F6 NGTBdI01QCCq NHzjcY9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTPSClZXzsd{Bi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjZzIN88US=> NGHXPVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxPVU2PSd-MkSxNVk2PTV:L3G+
HepG2 MX3BcpRqdWGuYYLpZYwh[XO|YYm= M2LaZWFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGW6bz3ldpl1cHKxY4n0bYMh\m:{bTDv[kBRdGG|bX;kbZVuKGKncnfo[YkhcW6oZXP0[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVAhRSByLkG1JO69VS5? NHXRWog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pyd-MkS5NFQ6Pjd:L3G+
HepG2 NWroTIJtSW62aYDsZZNud2SrYXygZZN{[Xl? NVKw[2p3PTNiaILz MXHBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KGW6b3XyfZRpem:leYTpZ{1{fGGpZTDv[kBRdGG|bX;kbZVuKGKncnfo[YkhSU6NQTDpcoZm[3SnZDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC1N{BpenNiYomgSGFRUSC|dHHpcolv\y2kYYPl[EBu\XSqb3SsJGlEPTBiPTCwMlE2KM7:TT6= MmLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{NEGxNVIoRjJ6MkSxNVEzRC:jPh?=
Sf9 MUHGeY5kfGmxbjDhd5NigQ>? NYnxZ3FxOiCqcoO= MnLCTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKRFHDMVIh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDT[lkh[2WubIOgeZNqdmdiRnz1c5Ih\GViTInzJIF{KHO3YoP0doF1\SCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkAyOCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiS3mgQUAxNjBzNjFOwG0v Mm\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg2OTl2Mz:nQmNpTU2ETEyvZV4>
HEK293-F MULGeY5kfGmxbjDhd5NigQ>? NGHvUZIzKGi{cx?= MY\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEiGQVOtPEBmgHC{ZYPz[YQhcW5iSFXLNlk{NUZiY3XscJMhfXOrbnegSox2d3JiZHWgUJl{KGG|IIP1ZpN1emG2ZTDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygT4khRSByLkCxOkDPxE1w MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFUyQTR|Lze+R4hGVUKOPD;hQi=>
Sf9 M4O5WmZ2dmO2aX;uJIF{e2G7 MkXmNkBpenN? NFe5[lNKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFjERWMuOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6|ZXP0JHNnQSClZXzsd{B2e2mwZzDGcJVweiCmZTDMfZMh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDFyIH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDLbUA:KDBwMEG2JO69VS5? NFnwWY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDVzOUSzM{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot p-JAK2 / JAK2 / p-STAT5 / STAT5 / p-FLT3 / FLT3 22829971
In vivo Administration of SB939 (25 mg/kg to 100 mg/kg) displays a dose-dependent antitumor efficacy in a xenograft mice model of human colorectal cancer (HCT-116). This is approximately twice as efficacious as SAHA: SB939 causing a tumor growth inhibition of 94% versus 48% by SAHA with both at the maximum tolerated dose. Oral administration of SB939 at a dose of 50 mg/kg or 75 mg/kg in the APCmin genetic mice model of early-stage colon cancer markedly reduces the number of tumors , decreases cumulative hemocult scores and increases hematocrit values more effectively than 5-fluorouracil. [1]

Protocol (from reference)

Kinase Assay:[1]
  • HDAC enzyme assay:

    All recombinant HDAC enzymes, with the exception of SIRT1, are cloned and expressed in S*BIO. The reaction mix containing 2.5 or 5 μL of the HDAC isoenzyme, assay buffer (25 mM Tris-HCl, pH 7.5; 137 mM NaCl; 2.7 mM KCl, 1 mM MgCl2 and 1 mg/mL BSA), different concentrations of SB939, and the fluorogenic deacetylase substrate Flour de LysTM in a total reaction volume of 33 μL is incubated at room temperature for 2 hours. 16 μL of Flour de LysTM developer is added and incubated for an additional 10 minutes. The emitted light is measured at 460 nm in a microplate reader. IC50 values are generated using the XLfit software.

Cell Research:[1]
  • Cell lines: HCT116, A2780, ACHN, MCF7, HL-60, et al.
  • Concentrations: Dissolved in DMSO (stock concentration, 10 mM), final concentrations 1.5 nM to 100 μM
  • Incubation Time: 96 hours
  • Method: Cells are seeded in 96-well plates in the log growth phase at a predetermined optimal density, and rested for 24 hours (adherent cells) or 2 hours (suspension cells), respectively. They are exposed to different concentrations of SB939 for 96 hours. Cell proliferation assays are done using either the CyQUANT cell proliferation assay kit for adherent cells or the CellTiter96 Aqueous One solution cell proliferation kit for suspension cells.
  • (Only for Reference)
Animal Research:[1]
  • Animal Models: BALB/c nude mice bearing HCT-116 human colon cancer xenografts, Male and APCmin mice
  • Dosages: 25, 50, 75, or 100 mg/kg
  • Administration: Oral gavage once daily
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 72 mg/mL
(200.84 mM)
Ethanol 27 mg/mL
(75.31 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.

30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 358.48
Formula

C20H30N4O2

CAS No. 929016-96-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02118909 Completed Drug: Pracinostat|Drug: Itraconazole|Drug: Ciprofloxacin Healthy Volunteers|Non-smokers Helsinn Healthcare SA May 2014 Phase 1
NCT02058784 Completed Drug: pracinostat Healthy Volunteers|Moderate to Heavy Smokers|Non-smokers Helsinn Healthcare SA|Celerion February 2014 Early Phase 1
NCT01112384 Completed Drug: SB939 Metastatic Sarcoma NCIC Clinical Trials Group|S*BIO|Canadian Cancer Trials Group March 18 2010 Phase 2
NCT00741234 Completed Drug: SB939|Drug: Azacitidine Solid Tumors|Hematologic Malignancies|Myelodysplastic Syndrome S*BIO April 2007 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pracinostat (SB939) | Pracinostat (SB939) supplier | purchase Pracinostat (SB939) | Pracinostat (SB939) cost | Pracinostat (SB939) manufacturer | order Pracinostat (SB939) | Pracinostat (SB939) distributor